Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Contract Manufacturing Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global biopharmaceuticals contract manufacturing market is expected to grow from $16.54 billion in 2022 to $18.31 billion in 2023 at a compound annual growth rate (CAGR) of 10.6%. The biopharmaceuticals contract manufacturing market is expected to reach $26.88 billion in 2027 at a CAGR of 10%.
Major players in the biopharmaceuticals contract manufacturing market are Boehringer Ingelheim GmbH, Lonza Group, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, Samsung BioLogics, AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis AG, Cambrex Corporation, and Emergent BioSolutions.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Biopharmaceutical contract manufacturing refers to a process in which a biopharmaceutical company hires a third-party manufacturer to produce their drugs or biologic products on their behalf. It is utilised when pharmaceutical businesses employ the facilities of other companies to manufacture pharmaceuticals under their own brand. It is identical to private label or third-party production.
The main products of biopharmaceutical contract manufacturing include biologics, monoclonal antibodies (mABs), recombinant proteins, vaccines, antisense, mai and molecular therapy and biosimilars. Monoclonal antibodies (MABs) refer to lab-made proteins that function in human bodies similarly to antibodies. They are sourced from mammalian and non-mammalian and the services offered include process development, fill and finish operations, analytical and QC studies and packaging for applications in clinical and commercial purposes.
Product innovations are a key trend gaining popularity in the biopharmaceuticals contract manufacturing market. Major companies operating in the biopharmaceutical contract manufacturing market are developing innovative products to sustain their position in the market.
For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology research company, and Elektrofi, a US-based biotechnology company specializing in drug formulation and delivery innovations, entered into a strategic contract manufacturing agreement to support the commercial production of Elektrofi's ground-breaking ultra-high concentration subcutaneous products. Elektrofi's proprietary microparticle technology enables small-volume injections of biologics such as monoclonal antibodies, therapeutic proteins, and other large-molecule medications important for human health. Elektrofi's platform technology allows patients to self-inject medicines at home rather than in a hospital setting, overcoming the difficulties of administering biologic-based medications.
In June 2022, Asahi Kasei Medical Co. Ltd., a Japan-based chemical company, acquired Bionova Scientific, LLC, for an undisclosed amount. With the acquisition of Bionova Scientific, Asahi Kasei Medical will be able to expand its bioprocess business by adding a biopharmaceutical CDMO (contract development and manufacturing organization) and reaching a broader customer base, including those developing the most cutting-edge next-generation biopharmaceuticals. Bionova Scientific, LLC is a US-based company that offers biopharmaceutical firms contract process development services and GMP-compliant contract manufacturing services.
North America was the largest region in the biopharmaceutical contract manufacuring market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biopharmaceutical contract manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the biopharmaceutical contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increasing demand for biologics is expected to propel the growth of the biopharmaceutical contract manufacturing market going forward. Biologics are products manufactured from living organisms or containing pieces made from them, such as those derived from humans, animals, or microbes, using biotechnology.
They are utilized to treat various diseases and ailments and provide the most cutting-edge therapies currently available. The biologics contract manufacturing industry is expanding due to the expanding biologics pipeline, the complexity of the production process, and firms focusing on their core capabilities, several pharmaceutical and biotechnology businesses are currently outsourcing a wide range of tasks, from commercial-scale manufacturing to early-stage drug research.
For instance, in December 2021, IQVIA Inc, a US-based provider of commercial outsourcing and biopharmaceutical development services, released a report stating that by 2021, biologics will account for 34% of all medical expenditures in Europe, with a value of €78.6 billion (US $86.29 billion) with a five-year compound annual growth rate (CAGR) of 10.5%. Therefore, the increasing demand for biologics is driving the growth of the biopharmaceutical contract manufacturing market.
The biopharmaceutical contract manufacturing market includes revenues earned by entities providing services such as formulation development, GMP manufacturing and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 275 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $18.31 billion |
| Forecasted Market Value (USD) by 2027 | $26.88 billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Biopharmaceuticals Contract Manufacturing Market Characteristics
3. Biopharmaceuticals Contract Manufacturing Market Trends And Strategies
4. Biopharmaceuticals Contract Manufacturing Market - Macro Economic Scenario
4.1. COVID-19 Impact On Biopharmaceuticals Contract Manufacturing Market
4.2. Ukraine-Russia War Impact On Biopharmaceuticals Contract Manufacturing Market
4.3. Impact Of High Inflation On Biopharmaceuticals Contract Manufacturing Market
5. Biopharmaceuticals Contract Manufacturing Market Size And Growth
5.1. Global Biopharmaceuticals Contract Manufacturing Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Biopharmaceuticals Contract Manufacturing Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Biopharmaceuticals Contract Manufacturing Market Segmentation
6.1. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Biologics
- Monoclonal Antibodies (MABs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, And Molecular Therapy
- Biosimilars
6.2. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Mammalian
- Non-mammalian
6.3. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Process Development
- Fill And Finish Operations
- Analytical And QC studies
- Packaging
6.4. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Clinical
- Commercial
7. Biopharmaceuticals Contract Manufacturing Market Regional And Country Analysis
7.1. Global Biopharmaceuticals Contract Manufacturing Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Biopharmaceuticals Contract Manufacturing Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/nlfmup
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
